Extensive Prospective Validation Study of the NightOwl Home Sleep Apnea Test
Launched by ECTOSENSE NV · Aug 15, 2018
Trial Information
Current as of May 17, 2025
Unknown status
Keywords
ClinConnect Summary
The purpose of this prospective validation study is the evaluation of the accuracy of the NightOwl HSAT to derive parameters relevant for the diagnosis of sleep apnea. The NightOwl HSAT comprises a finger or forehead mounted sensor and an automated analytics software. The sensor measures double-wavelength photo-plethysmography and accelerometry. The analytics software automatically interprets the sensor data and derives a measure of sympathetic activation of the autonomic nervous system, oxygen saturation, instantaneous pulse rate and activity. For each patient in the cohort, the AHI derive...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • indication for a sleep study
- Exclusion Criteria:
- • Mentally disabled people
About Ectosense Nv
Ectosense NV is a pioneering medical technology company dedicated to advancing sleep health through innovative diagnostic solutions. With a focus on developing non-invasive monitoring devices, Ectosense aims to empower patients and healthcare providers with accurate and actionable insights into sleep disorders, particularly obstructive sleep apnea. By leveraging cutting-edge technology and clinical research, the company strives to enhance patient outcomes and improve the overall management of sleep-related conditions, positioning itself as a leader in the field of sleep medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genk, Limburg, Belgium
Patients applied
Trial Officials
Frederik Massie, ir.
Study Director
Ectosense NV
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials